CD33 and acute myeloid leukemia: Tambaro et al. at the MD Anderson Cancer Center used autologous CD33 CAR-T cells in three adult R/R AML patients: two of the three patients developed grade 3 toxicity, and all three patients died from leukemia progression [67].